EPROSARTAN MESYLATE (eprosartan mesylate) by AbbVie is mechanism of action eprosartan: angiotensin ii (formed from angiotensin i in a reaction catalyzed by angiotensin-converting enzyme [kininase ii]), a potent vasoconstrictor, is the principal pressor agent of the renin-angiotensin system. Approved for hypertension. First approved in 2011.
Drug data last refreshed 1w ago
Mechanism of Action Eprosartan: Angiotensin II (formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme [kininase II]), a potent vasoconstrictor, is the principal pressor agent of the renin-angiotensin system. Angiotensin II also stimulates aldosterone synthesis and…
Worked on EPROSARTAN MESYLATE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension